Generalized Wegener's granulomatosis responding to sulfamethoxazole-trimethoprim monotherapy

Internal Medicine

Volumn 40, Issue 7, 2001, Pages 666-670

  Ohtake, Takayasu ^a   Kobayashi, Shuzo ^b   Honjou, Yumiko ^a   Shirai, Toshihiro ^a   Takayanagi, Shigekazu ^a   Tohyama, Kyoko ^a   Tokura, Yoshiki ^c   Kimura, Masato ^d  

^a Fujinomiya City General Hospital   (Japan)

^b SHONAN KAMAKURA GENERAL HOSPITAL   (Japan)

^c HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

IL 6; Proteinuria; Soluble IL 2 receptor

Indexed keywords

COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; STEROID;

AGED; ARTICLE; CASE REPORT; DRUG EFFICACY; FEMALE; HUMAN; HUMAN TISSUE; PROTEINURIA; TREATMENT OUTCOME; URINARY EXCRETION; WEGENER GRANULOMATOSIS;

EID: 0034859341     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.40.666     Document Type: Article

References (27)

1. DeRemee RA, McDonald TJ, Weiland LH. Wegener's granulomatosis: Observation on treatment with antimicrobial agents. Mayo Clin Proc 60: 27-32, 1985.
2. West BC, Todd JR, King JW. Wegener's granulomatosis and trimethoprimsulfamethoxazole. Complete remission after a twenty-year course, Ann Intern Med 106: 840-842, 1987.
3. Axelson JA, Clark RH, Ancerewicz S. Wegener's granulomatosis and trimethoprim-sulfamethoxazole. Ann Intern Med 107: 600, 1987 (letter).
4. Spiera H, Lawson W, Weinrauch H. Wegener's granulomatosis treated with sulfamethoxazole-trimethoprim. Report of a case. Arch Intern Med 148: 2065-2066, 1988.
5. Israel HL. Sulfamethoxazole-trimethoprim therapy for Wegener's granulomatosis. Arch Intern Med 148: 2293-2295, 1988.
6. Yuasa K, Tokitsu M, Goto H, Kato H, Shimada K. Wegener's granulomatosis: Diagnosis by transbronchial lung biopsy, evaluation by gallium scintigraphy and treatment with sulfamethoxazole/trimethoprim. Am J Med 84: 371-372, 1988 (letter).
7. Boudes P. The treatment of Wegener's granulomatosis with sulfamethoxazole and trimethoprim. Arch Intern Med 149: 1467-1471, 1989 (letter).
8. Rasmussen N, Petersen J, Remvig L, Andersen V. Treatment of Wegener's granulomatosis with trimethoprim-sulfamethoxazole. APMIS Suppl 19: 61-62, 1990.
9. Valeriano-Marcet J, Spiera H. Treatment of Wegener's granulomatosis with sulfamethoxazole-trimethoprim. Arch Intern Med 151: 1649-1652, 1991.
10. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener's granulomatosis: An analysis of 158 patients. Ann Intern Med 116: 488-498, 1992.
11. Puolijoki H, Liippo K, Raitio M, Tala E. Wegener's granulomatosis - Treatment under revision? Respiration 59: 116-118, 1992.
12. McRae D, Buchanan G. Long-term sulfamethoxazole-trimethoprim in Wegener's granulomatosis. Arch Otolaryngol Head Neck Surg 119: 103-105, 1993.
13. Reinhold-Keller E, Groot K, Rudert H, Nolle B, Heller M, Gross WL. Response to trimethoprim/sulfamethoxazole in Wegener's granulomatosis depends on the phase of disease. Q J Med 89: 15-23, 1996.
14. Stegeman CA, Cohen Tervaert JW, de Jong PE, Kallenberg CGM, and Dutch Co-Trimoxazole Wegener Study Group. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevension of relapses of Wegener's granulomatosis. N Engl J Med 335: 16-20, 1996.
15. Kallenberg CGM, Stegeman CA, Cohen Tervaert JW. Staphylococcus aureus, trimethoprim-sulfamethoxazole, and Wegener's granulomatosis. Sarcoidosis Vasc Diffuse Lung Dis 13: 253-255, 1996.
16. Leavitt RY, Fauci AS, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 33: 1101-1107, 1990.
17. Kallenberg CGM, Cohen Tervaert LW, Stegeman CA. Criteria for disease activity in Wegener's granulomatosis: A requirement for longitudinal clinical studies. APMIS Suppl 19: 37-39, 1990.
18. Cohen Tervaert JW, van der Woude FJ, Fauci AS, et al. Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch Intern Med 149: 2461-2465, 1989.
19. Egner W, Chapel HM. Titration of antibodies against neutrophil cytoplasmic antigens is useful in monitoring disease activity in systemic vasculitides. Clin Exp Immunol 82: 244-249, 1990.
20. George J, Levy Y, Kallenberg COM, Shoenfeld Y. Infections and Wegener's granulomatosis - a cause and effect relationship? Q J Med 90: 367-373, 1997.
21. Mayet WJ, Hermann E, Csermor E. In vitro interaction of cANCA with human endothelial cells. Advances in Experimental Medicine and Biology. Fourth International Workshop on ANCA. Plenum 2, London, 1992.
22. Falk JR, Terrell RS, Charles LA, Jennette JC. Antineutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 87: 4115-4119, 1990.
23. Mayet WJ, Schwarting A, Meyer zum Buschenfelde KH. Cytotoxic effects of antibodies to proteinase 3 (C-ANCA) on human endothelial cells. Clin Exp Immunol 97: 458-465, 1994.
24. Brouwer E, Huitema MG, Mulder AH, et al. Neutrophil activation in vitro and in vivo in Wegener's granulomatosis. Kidney Int 45: 1120-1131, 1994.
25. Anderson R, Grabow G, Oosthuizen R, Theron A, Van Rensburg AJ. Effects of sulfamethoxazole and lrimethoprim on human neutrophil and lym-phocyte functions in vitro: in vivo effects of co-trimoxazole. Antimicrob Agents Chemother 17: 322-326, 1980.
26. McCarthy ET, Sharma R, Sharma M, et al. TNF-alpha increases albumin permeability of isolated rat glomeruli through the generation of superoxide. J Am Soc Nephrol 9: 433-438, 1998.
27. Nakamura T, Ebihara I, Takahashi T, Yamamoto M, Tomino Y, Koide H. Increased interleukin 6 mRNA expression by peripheral blood T cells from patients with IgA nephropathy. Autoimmunity 15: 171-179, 1993.